An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer

Inclusion Criteria: women with a recent diagnosis of T1 or T2 noninvasive breast cancer by large core needle or excisional biopsy confirmation that tissue was processed in methods acceptable to protocol and sufficient tissue remains post diagnostic analyses to perform research assessments reexcision planned within 10 days to 6 weeks from study start Exclusion Criteria: no hormone replacement therapy within 90 days prior to biopsy no history of asthma, allergy ASA, NSAIDS, celecoxib of other COX-2 inhibitors for a chronic non-oncological condition with the excision of low dose ASA (160 mg daily) during 4 weeks prior to biopsy and for the duration of the study no celecoxib or rofecoxib use within one month of biopsy no history of gastrointestinal ulcer or ulcerative colitis requiring treatment no current anticoagulants no neoadjuvant antihormone or chemotherapy as treatment following biopsy prior to study entry or concurrently with participation on study no aromatase inhibitor in the six months prior to participation no concomitant lithium no known significant bleeding disorder